Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMA3DKO)

Drug Name
RIST4721 Drug Info
Synonyms
vimnerixin; AZD4721; RIST4721; AZD-4721; RIST-4721; X09ORN2BF0; 1418112-77-2; UNII-X09ORN2BF0; AZD-4721 [WHO-DD]; 1-Azetidinesulfonamide, N-(6-((1R,2S)-2,3-dihydroxy-1-methylpropoxy)-2-(((4-fluorophenyl)methyl)thio)-4-pyrimidinyl)-3-methyl-; vimnerixin [INN]; Azd 4721; CHEMBL5095217; SCHEMBL14579049; GTPL12100; AZD 4721 [WHO-DD]; AZD4721;RIST4721; AKOS040756752; compound 4 [WO2019055509A1]; MS-28748; HY-145640; CS-0377236; F83913; N-(6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}-2-{[(4-fluorophenyl)methyl]sulfanyl}pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide; N-[6-[(1R,2S)-2,3-Dihydroxy-1-methylpropoxy]-2-[[(4-fluorophenyl)methyl]thio]-4-pyrimidinyl]-3-methyl-1-azetidinesulfonamide; N-[6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide
Indication
Disease Entry ICD 11 Status REF
Hidradenitis suppurativa ED92.0 Phase 2 [1]
Palmoplantar pustulosis EA90.42 Phase 2 [2]
Cross-matching ID
PubChem CID
71209600
TTD Drug ID
DMA3DKO

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Antagonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 2.722 1.202 1.202 0.848
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hidradenitis suppurativa
ICD Disease Classification ED92.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 8.82E-01 -0.23 -0.21
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 1.34E-01 0.21 0.19
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05348681) A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05194839) A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis. U.S.National Institutes of Health.
3 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.